MARKET

BNTX

BNTX

BIONTECH
NASDAQ

Real-time Quotes | Nasdaq Last Sale

155.66
+6.56
+4.40%
Opening 13:44 07/01 EDT
OPEN
148.00
PREV CLOSE
149.10
HIGH
157.19
LOW
147.20
VOLUME
962.41K
TURNOVER
98.58M
52 WEEK HIGH
457.93
52 WEEK LOW
117.08
MARKET CAP
37.83B
P/E (TTM)
2.750
1D
5D
1M
3M
1Y
5Y
FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants
Benzinga · 7h ago
Omicron: Experts want more data to guide US targeting of fall boosters
The FDA is asking COVID-19 vaccine makers to test and produce boosters that target both the original and new BA.4/BA.5 strains of the virus by fall.
Yahoo Finance · 1d ago
This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50. Comirnaty U.S. pricing per dose has in...
Benzinga · 1d ago
PFE Stock Rises as Pfizer Requests FDA Approval of Covid-19 Treatment Paxlovid
Investor Place · 1d ago
FDA says COVID-19 boosters should be updated to combat two omicron subvariants
The Food and Drug Administration on Thursday told COVID-19 vaccine makers that plan to update their boosters to add a BA.4 and BA.5 spike protein component to the new shots that are in development. These "bivalent" boosters should equally target the two su...
marketwatch.com · 1d ago
FDA requests manufacturers to update vaccines for latest Omicron subvariants
The U.S. Food and Drug Administration (FDA) said Thursday that the agency advised COVID-19 vaccine developers to update their shots adding a component to protect against the latest subvariants of Omicron.In a statement, FDA’s vaccine chief...
Seekingalpha · 1d ago
Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply
Pfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.
Zacks · 1d ago
Update: Pfizer, BioNTech Enter $3.2 Billion Deal to Provide 105 Million COVID-19 Vaccines Doses to US; Shares Rise
MT Newswires · 1d ago
More
No Data
Learn about the latest financial forecast of BNTX. Analyze the recent business situations of BIONTECH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

11.76%Strong Buy
29.41%Buy
58.82%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BNTX stock price target is 252.14 with a high estimate of 364.82 and a low estimate of 166.97.
High364.82
Average252.14
Low166.97
Current 157.50
EPS
Actual
Estimate
3.947.8811.8215.76
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 341
Institutional Holdings: 34.92M
% Owned: 14.37%
Shares Outstanding: 243.02M
TypeInstitutionsShares
Increased
105
4.18M
New
49
3.24M
Decreased
77
6.67M
Sold Out
107
1.91M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.90%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chairman - Supervisory/Independent Director
Helmut Jeggle
Chief Executive Officer/Management Board
Ugur Sahin
Chief Financial Officer
Jens Holstein
Chief Operating Officer/Management Board
Sierk Poetting
Chief Compliance Officer/Management Board
Sean Marett
Management Board
Ryan Richardson
Management Board
Oezlem Tuereci
Independent Director/Supervisory Board
Christoph Huber
Independent Director/Supervisory Board
Michael Motschmann
Independent Director/Supervisory Board
Ulrich Wandschneider
No Data
No Data
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Webull offers kinds of BioNTech SE - ADR stock information, including NASDAQ:BNTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNTX stock methods without spending real money on the virtual paper trading platform.